Related Experiment Video
Updated: Apr 7, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Changing Treatment Paradigms in Metastatic Breast Cancer: Lessons Learned
Cesar A Santa-Maria1, William J Gradishar1
1Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Abstract:
Advances in understanding tumor biology, particularly signaling pathways, have led to the development and approval of many novel agents and have changed the landscape of therapy for patients with metastatic breast cancer. This review highlights some of the recent successes and failures in breast cancer drug development, including strategies to overcome endocrine and human epidermal growth factor 2-neu (HER2) resistance, targeting triple-negative breast cancers (which do not express the HER2, estrogen, and progesterone receptors) through novel receptors, harnessing the immune system, and new ways of targeting angiogenesis. For patients with metastatic breast cancer, expanding therapeutic options through clinical trial participation is a crucial part of modern oncology practice. As we continue to learn how to use targeted therapies in the context of genomic medicine, analysis of the tumor in real-time may become increasingly important, giving researchers the information needed to start combining therapies in a biologically informed manner.
Insights
Recent advances in metastatic breast cancer therapy include novel agents targeting signaling pathways and resistance mechanisms. Clinical trials and real-time tumor analysis are crucial for developing personalized, combination treatment strategies.
Area of Science:
- Oncology
- Pharmacology
- Genomic Medicine
Background:
- Understanding tumor biology and signaling pathways has revolutionized metastatic breast cancer treatment.
- Novel therapeutic agents have been developed and approved, significantly altering patient care.
Purpose of the Study:
- To review recent successes and failures in breast cancer drug development.
- To explore strategies for overcoming endocrine and HER2 resistance.
- To discuss novel approaches for targeting triple-negative breast cancers, angiogenesis, and harnessing the immune system.
Main Methods:
- Review of recent literature on breast cancer drug development.
- Analysis of therapeutic strategies including targeted therapies, immunotherapy, and anti-angiogenesis.
- Discussion of clinical trial participation and genomic medicine applications.
Main Results:
- Highlighting successes and failures in developing novel agents for metastatic breast cancer.
- Identifying key strategies to overcome treatment resistance (endocrine, HER2).
- Exploring new targets for triple-negative breast cancer and angiogenesis.
Conclusions:
- Expanding therapeutic options through clinical trials is vital for patients with metastatic breast cancer.
- Real-time tumor analysis in genomic medicine will enable biologically informed combination therapies.
- Continued research into novel receptors, immunotherapy, and angiogenesis is essential.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
02:56Treatment Resistent Cancers
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:30Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...